+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID05972655

Phase II Study of Modified Short-Course Radiation with CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Led by Sir Run Run Shaw Hospital · Updated on 2025-01-09

32

Participants Needed

1

Research Sites

88 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for patients with microsatellite stable MSS middle and low rectal cancer. This open-label, phase II clinical trial involves 32 patients and aims to assess the effectiveness of modified short-course radiation combined with chemotherapy CAPOX and a PD-1 inhibitor called Tislelizumab. The main goal is to measure the rate of complete tumor response after treatment, while also examining organ preservation, tumor shrinkage, long-term outcomes, and side effects. Participants will receive a specialized short-course radiation targeting only the tumor bed without affecting surrounding lymph nodes. This radiation is given as 25 Gy over 5 sessions. Alongside radiation, patients will be treated with chemotherapy drugs oxaliplatin and capecitabine, plus Tislelizumab, a PD-1 antibody. These therapies are given in cycles every 3 weeks for a total of four cycles. After completing treatment, patients will undergo surgery to remove the tumor area. During the study, participants will be closely monitored through various assessments including tumor response and regression evaluation within 10 days after surgery. Researchers will also track local recurrence, disease-free survival, overall survival, adverse effects, and quality of life for up to five years post-surgery. Specific questionnaires and scoring systems like QLQ-CR29, QLQ-C30, and the Wexner score will be used to assess patient well-being and rectal function throughout the follow-up period.

CONDITIONS

Brief Title

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Research Team

Z

Zhangfa Song, M.D, PH.D

C

Cheng Cai, master

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here